Join
Live feed
·
PRReleasevia Quantisnow
GSK plc logo
Mersana Therapeutics Inc. logo

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

ByQuantisnow·Wall Street's wire, on your screen.
GSK· GSK plcMRSN· Mersana Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GSK (GSK plc), MRSN (Mersana Therapeutics Inc.) and more on Quantisnow.